全球生物制药产业概况

2009442ChinMedBiotechnol,April2009,Vol.4,No.285··[1-2]198220100Gaucher’s[3]Gaucher’sAldurazymeNaglazymeCerezymeFabrazymePulmozyme——VII/VIII/IXNovoSevenReFactoBeneFix54anti-CD20Rituxananti-EGFRIIHerceptinG-CSFanti-VEGFAvastin40t-PATNK-tPArPAanti-TNFαEnbrelRemicadeHumira19981015%~[e-mail]2009-03-09862009442ChinMedBiotechnol,April2009,Vol.4,No.220081231FDA992007291030%20071101010801%2007401675anti-TNFαEnbrelRemicadeBanti-CD20Rituxananti-EGFRIIHerceptinanti-VEGFAvastin200715683599.5%5620076anti-TNFαEPOβ-675%CHO320076FDA4[4]TNF-αagalsidase-αEPO-βPTHTNF-α3agalsidase-βFabrazymeEPO-αEPOGENPTH1-34FORTEO2basicfibroblastgrowthfactorbFGFanti-IL-6RtocilizumabActemraRochebFGFanti-IL-6RIII2009FDA[5-6]20081231FDA99[1-2]FDA2009442ChinMedBiotechnol,April2009,Vol.4,No.2874PEGPEG261-343HumulogApidraLantusα-2aα-2bβ-1bγG-CSF-1Ra-2-11tPArPA-IL2OspAKGFIGF-1FORTICALanti-VEGFLucentisPEGanti-TNFαTPO-Fc2005G-CSFαβ-1banti-VEGFLucentisPEGanti-TNFαTPO-Fc10rasburicaseGlucaGenGM-CSFrhPDGF-BBHPVGardasilNovolinNovoLogLevemir2006HPVGardasil2AbbokinaseIFNα-N3AlferonIFNα-n1WellferonApligrafDermagraftOrCelCarticel1%59291EPO-αAranespEPO-αEPOGENProcritEPO-βNeoRecormonIFNβ-1aRebifAvonexVIIIRecombinateKogenateVIIaNovoSevenCerezyme1030CHONSO2136361000/3anti-TNFαEnbrelRemicadeHumiraEnbrelHumiraanti-CD11aRaptivaCTL4-FcOrenciaLFA3-FcAmevive3GenentechRoche3RituxanHerceptinAvastinHER-2+PhRMA882009442ChinMedBiotechnol,April2009,Vol.4,No.22008633192FDAFDAFDA9930200830040%95EnbrelRituxanRemicadeHerceptinAvastin40VIII22CHO50pg10000L20000L8~1220086000kg50000~200000EPOG-CSF~8015%~20%R&D19821997G-CSF10EPOG-CSFINF-α1994~19971001997RituxanRemicadeHerceptinEnbrel1015%~33%120078402008900EPOG-CSFINF-αIL-21990[7][1]HuXW,ChenHP,TangZM,etal.ComparisonofapprovalbiomedicinesamongUSA,EUandChina.ChinaBiotechnol,2005,25(2):82-94.(inChinese),,,..,2005,25(2):82-94.[2]DepartmentofHigh-TechIndustryoftheNationalDevelopmentandReformCommissionofthePeople’sRepublicofChina,ChineseSocietyofBiotechnology.Thepresentandthefutureofglobalbiopharmaceuticalindustry//HuXW,MaQJ.AnnualReportonBioindustryinChina,2005.Beijing:ChinaChemicalIndustryPress,2006:43-92.(inChinese),.//,.2005.:,2006:43-92.[3]DepartmentofHigh-TechIndustryoftheNationalDevelopmentandReformCommissionofthePeople’sRepublicofChina,ChineseSocietyofBiotechnology.Thepresentandthefutureofbioindustry:biopharmaceuticals//HuXW,MaQJ.AnnualReportonBioindustryinChina,2006.Beijing:ChinaChemicalIndustryPress,2007:45-74.(inChinese),.//,.2006.:,2007:45-74.[4]TsujiK,TsutaniK.Approvalofnewbiopharmaceuticals1999-2006:comparisonoftheUS,EUandJapansituations.EurJPharmBiopharm,2008,68(3):496-502.[5]HuXW,ChenHP,TangZM,etal.Thepresentandthefutureofbiopharmaceuticals(1):historyandtoday’smarket.ChinaBiotechnol,2004,24(12):94-100.,,,.():.,2004,24(12):94-100.[6]HuXW,ChenHP,TangZM,etal.Thepresentandthefutureofbiopharmaceuticals(2):trendsandprospects.ChinaBiotechnol,2005,25(1):86-93.,,,.():.,2005,25(1):86-93.[7]HuX,MaQ,ZhangS.BiopharmaceuticalsinChina.BiotechnolJ,2006,1(11):1215-1224.